AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9170564 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern judgment
Number of subjects: 0
Study 9170564 — intervention group
Group type: EXPERIMENTAL
Intervention: Generation test
Number of subjects: 0
Study 9170564 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit knowledge test
Number of subjects: 0
Study 1416159 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl infusion
Number of subjects: 29
Study 1416159 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl infusion
Number of subjects: 29
Study 1416159 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 4019944 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with P/S ratio 1.3
Number of subjects: 14
Study 4019944 — intervention group
Group type: COMPARATOR
Intervention: Diet with P/S ratio 0.7
Number of subjects: 14
Study 30513433 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation combined with lifestyle intervention (LI) for 12 weeks
Number of subjects: 70
Study 30513433 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention (LI) alone
Number of subjects: 70
Study 29422091 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially supervised exercise intervention with individual counselling to increase vigorous physical activity (PA) by at least 3 hours per week, daily PA documentation, step counter, and monthly phone calls for the first 6 months.
Number of subjects: 292
Study 29422091 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially supervised exercise intervention with motivational feedback.
Number of subjects: 292
Study 29422091 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 292
Study 27106715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis administration
Number of subjects: 61
Study 27106715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine administration
Number of subjects: 61
Study 27106715 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 61
Study 27106715 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 61
Study 24827934 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression instruction
Number of subjects: 64
Study 24827934 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance instruction
Number of subjects: 64
Study 24827934 — intervention group
Group type: COMPARATOR
Intervention: No-regulation (Control) instruction
Number of subjects: 64
Study 21904224 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline (HTS)
Number of subjects: 20
Study 21904224 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline
Number of subjects: 20
Study 20091678 — intervention group
Group type: EXPERIMENTAL
Intervention: LB80380 (30, 60, 90, 150, 240 mg)
Number of subjects: 65
Study 20091678 — intervention group
Group type: EXPERIMENTAL
Intervention: LB80380
Number of subjects: 65
Study 18166199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) at 30 mg/kg/day
Number of subjects: 33
Study 18166199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) at 20 mg/kg/day
Number of subjects: 33
Study 18166199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) at 40 mg/kg/day
Number of subjects: 33
Study 18166199 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 control fibroblast cell line)
Number of subjects: 33
Study 16182221 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-ultrasound fusion brachytherapy
Number of subjects: 54
Study 12574567 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke patients
Number of subjects: 0
Study 12574567 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 10476888 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 85
Study 8558634 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (200 micrograms subcutaneously once a week)
Number of subjects: 30
Study 8558634 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-2 and interferon-alpha 2b (4 x 4.8 x 10(6) IU/m.2 interleukin-2 subcutaneously on days 1 and 22, 2 x 4.8 x 10(6) IU/m.2 on days 2 and 23, and 2 x 2.4 x 10(6) IU/m.2 combined with interferon-alpha 2b subcutaneously at 3 x 10(6) IU/m.2 on days 3, 5, 24 and 26, and 6 x 10(6) IU/m.2 3 times weekly for 6 weeks)
Number of subjects: 30
Study 1831394 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (ISR)
Number of subjects: 20
Study 1831394 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 20
Study 6361228 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 0.7 mg/kg orally administered
Number of subjects: 12
Study 6361228 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine 0.7 mg/kg three times daily
Number of subjects: 12
Study 6361228 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine 1.4 mg/kg three times daily
Number of subjects: 12
Study 31753781 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion
Number of subjects: 53
Study 30833204 — intervention group
Group type: EXPERIMENTAL
Intervention: Video coaching using Google Glass (intervention group, 20 participants)
Number of subjects: 42
Study 30833204 — intervention group
Group type: COMPARATOR
Intervention: Verbal coaching alone (control group, 22 participants)
Number of subjects: 42
Study 30392581 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain specific fatty acid (BSFA) supplementation (DHA and ArA) during pregnancy
Number of subjects: 86
Study 30392581 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 86
Study 26893551 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium + olodaterol (5/5 µg and 2.5/5 µg) via Respimat(®)
Number of subjects: 0
Study 26893551 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol + fluticasone propionate (50/500 µg and 50/250 µg) via Accuhaler(®)
Number of subjects: 0
Study 26893551 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium + olodaterol
Number of subjects: 0
Study 24535560 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 0
Study 24535560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22985134 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of treatment with one of 5 different dosing combinations (2 or 3 30-min treatments per week or 1, 2, or 3 60-min treatments per week)
Number of subjects: 228
Study 22985134 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weekly 60-min massages
Number of subjects: 228
Study 22985134 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 228
Study 20194546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal electrode placement at one and a half times seizure threshold
Number of subjects: 230
Study 20194546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitemporal electrode placement at one and a half times seizure threshold
Number of subjects: 230
Study 20194546 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral electrode placement at six times seizure threshold
Number of subjects: 230
Study 22858527 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone/Reductant/Patient Kit
Number of subjects: 14
Study 22858527 — intervention group
Group type: EXPERIMENTAL
Intervention: Reductant/Patient Kit
Number of subjects: 14
Study 22858527 — intervention group
Group type: COMPARATOR
Intervention: Fluoride free toothpaste (Control)
Number of subjects: 14
Study 16429658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily for 6 weeks
Number of subjects: 21
Study 16429658 — intervention group
Group type: COMPARATOR
Intervention: Finasteride 5 mg daily for 6 weeks
Number of subjects: 21
Study 12630022 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1, methylprednisolone, and C-tube drainage
Number of subjects: 13
Study 12630022 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 and steroid administration
Number of subjects: 13
Study 12630022 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative management with steroid, prostaglandin E1, and C-tube drainage
Number of subjects: 13
Study 10226860 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus diuretics
Number of subjects: 345
Study 10226860 — intervention group
Group type: COMPARATOR
Intervention: Digoxin plus diuretics
Number of subjects: 345
Study 8764421 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (Aterax) 1‐2 mg/kg
Number of subjects: 60
Study 8764421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8764421 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine and Placebo
Number of subjects: 60
Study 8764421 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication visit
Number of subjects: 60
Study 1860324 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard doses of epinephrine (1 mg iv every 5 mins)
Number of subjects: 15
Study 6354248 — intervention group
Group type: EXPERIMENTAL
Intervention: Reality orientation therapy
Number of subjects: 38
Study 6354248 — intervention group
Group type: COMPARATOR
Intervention: Diversional occupational therapy
Number of subjects: 38
Study 29426956 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice based on risk communication by a nurse counselor
Number of subjects: 528
Study 29426956 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 528
Study 29075381 — intervention group
Group type: EXPERIMENTAL
Intervention: milestones plus a 13‐item checklist with behavioral anchors
Number of subjects: 20
Study 29075381 — intervention group
Group type: COMPARATOR
Intervention: milestones alone
Number of subjects: 20
Study 25569274 — intervention group
Group type: EXPERIMENTAL
Intervention: BB-12-supplemented yogurt
Number of subjects: 40
Study 25569274 — intervention group
Group type: COMPARATOR
Intervention: Control yogurt (non-supplemented)
Number of subjects: 40
Study 23975236 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (60 μg/m(2)/wk) plus oral ribavirin (15 mg/kg/day)
Number of subjects: 107
Study 20937312 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 μg YIC therapeutic vaccine
Number of subjects: 242
Study 20937312 — intervention group
Group type: COMPARATOR
Intervention: Alum immunized control group
Number of subjects: 242
Study 18582568 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac extended release (ER) tablet using the novel dissolution test apparatus
Number of subjects: 24
Study 18582568 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac extended release (ER) tablet using the conventional dissolution apparatus (USP II)
Number of subjects: 24
Study 18582568 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentration versus time profiles after the administration of an ER tablet
Number of subjects: 24
Study 16904536 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 2727
Study 16904536 — intervention group
Group type: COMPARATOR
Intervention: LOCM
Number of subjects: 2727
Study 16904536 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol in CKD patients
Number of subjects: 2727
Study 16904536 — intervention group
Group type: COMPARATOR
Intervention: LOCM in CKD patients
Number of subjects: 2727
Study 16904536 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol in CKD + DM patients
Number of subjects: 2727
Study 16904536 — intervention group
Group type: COMPARATOR
Intervention: LOCM in CKD + DM patients
Number of subjects: 2727
Study 12952230 — intervention group
Group type: EXPERIMENTAL
Intervention: EBVD chemotherapy
Number of subjects: 264
Study 12952230 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy
Number of subjects: 264
Study 11113043 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective stent implantation
Number of subjects: 735
Study 11113043 — intervention group
Group type: COMPARATOR
Intervention: Guided PTCA
Number of subjects: 735
Study 9025802 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of slow release caffeine (SRC)
Number of subjects: 120
Study 9025802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 1815019 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-brushing mouthrinse used according to manufacturer's instructions
Number of subjects: 41
Study 1815019 — intervention group
Group type: COMPARATOR
Intervention: Normal oral hygiene practices (Control)
Number of subjects: 41
Study 6636394 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antimicrobial therapy (sulfamethoxazole)
Number of subjects: 78
Study 6636394 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic antimicrobial therapy)
Number of subjects: 78
Study 29994980 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest CBT (32.0-36.2°C)
Number of subjects: 99
Study 29994980 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle CBT (36.3-36.8°C)
Number of subjects: 99
Study 29994980 — intervention group
Group type: COMPARATOR
Intervention: Highest CBT (36.9-38.8°C)
Number of subjects: 99
Study 27400015 — intervention group
Group type: COMPARATOR
Intervention: 12 mL of a 1% lidocaine paracervical block
Number of subjects: 142
Study 27400015 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of a self-administered, 2% lidocaine gel
Number of subjects: 142
Study 24886960 — intervention group
Group type: EXPERIMENTAL
Intervention: Social marketing intervention (distribution of HPV vaccination posters and brochures, radio PSAs, online CME training)
Number of subjects: 194
Study 24886960 — intervention group
Group type: COMPARATOR
Intervention: Control counties (no intervention)
Number of subjects: 194
Study 22808699 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week lower-body resistance training program
Number of subjects: 28
Study 20214831 — intervention group
Group type: EXPERIMENTAL
Intervention: JinQi-Jiangtang tablets (JQJT)
Number of subjects: 400
Study 20214831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 18406211 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary LTG for at least 2 weeks prior to admission
Number of subjects: 9
Study 18406211 — intervention group
Group type: COMPARATOR
Intervention: Generic LTG therapy for at least 7 days
Number of subjects: 9
Study 15745374 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg/daily for 4 weeks)
Number of subjects: 40
Study 15745374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12115356 — intervention group
Group type: EXPERIMENTAL
Intervention: Azoles antifungal agents (fluconazole, itraconazole, ketoconazole, miconazole)
Number of subjects: 7014
Study 10195512 — intervention group
Group type: EXPERIMENTAL
Intervention: i.a. bupivacaine (30 mL of 0.25%) + clonidine (1 microg/kg) i.a.
Number of subjects: 50
Study 10195512 — intervention group
Group type: COMPARATOR
Intervention: i.a. bupivacaine (30 mL of 0.25%)
Number of subjects: 50
Study 10195512 — intervention group
Group type: EXPERIMENTAL
Intervention: i.a. bupivacaine (30 mL of 0.25%) + subcutaneous clonidine (1 microg/kg)
Number of subjects: 50
Study 10195512 — intervention group
Group type: EXPERIMENTAL
Intervention: i.a. bupivacaine (30 mL of 0.25%) + epinephrine (5 microg/mL)
Number of subjects: 50
Study 10195512 — intervention group
Group type: EXPERIMENTAL
Intervention: clonidine (1 microg/kg) in 30 mL of saline i.a.
Number of subjects: 50
Study 7559318 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder (MDD) group (n = 90)
Number of subjects: 1507
Study 7559318 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance Use Disorder (SUD) group (n = 42)
Number of subjects: 1507
Study 7559318 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 1,189)
Number of subjects: 1507
Study 2157640 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (intravenous plus oral)
Number of subjects: 37
Study 2157640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 2157640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (70 mg/m2)
Number of subjects: 37
Study 377476 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium169 synoviorthesis
Number of subjects: 7
Study 377476 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 7
Study 31027929 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV10 vaccine
Number of subjects: 424
Study 31027929 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (hepatitis A or B vaccine)
Number of subjects: 424
Study 28378139 — intervention group
Group type: EXPERIMENTAL
Intervention: Flippits (distraction cards)
Number of subjects: 210
Study 28378139 — intervention group
Group type: COMPARATOR
Intervention: Control group (no distraction)
Number of subjects: 210
Study 26561617 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fat intake (highest quintile)
Number of subjects: 7038
Study 26561617 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid (MUFA) intake (highest quintile)
Number of subjects: 7038
Study 26561617 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acid (PUFA) intake (highest quintile)
Number of subjects: 7038
Study 26561617 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acid (SFA) intake (highest quintile)
Number of subjects: 7038
Study 26561617 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-fat intake (highest quintile)
Number of subjects: 7038
Study 26561617 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric replacement of SFAs with MUFAs and PUFAs
Number of subjects: 7038
Study 26561617 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric replacement of trans fat with MUFAs
Number of subjects: 7038
Study 26561617 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA and MUFA intakes
Number of subjects: 7038
Study 26561617 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA from pastries and processed foods
Number of subjects: 7038
Study 23725307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tannase-converted green tea extract (TGE)
Number of subjects: 0
Study 23725307 — intervention group
Group type: COMPARATOR
Intervention: Normal green tea extract (NGE)
Number of subjects: 0
Study 21332729 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony-stimulating factor (G-CSF) injection in abdominal skin (Group A)
Number of subjects: 40
Study 21332729 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte-colony-stimulating factor (G-CSF) injection in lower adipose tissue-containing sites (arms and legs) (Group B)
Number of subjects: 40
Study 21332729 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 40
Study 19746751 — intervention group
Group type: EXPERIMENTAL
Intervention: Otocerum
Number of subjects: 90
Study 19746751 — intervention group
Group type: EXPERIMENTAL
Intervention: Taponoto
Number of subjects: 90
Study 19746751 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control group)
Number of subjects: 90
Study 17692723 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin gel microspheres 0.04%
Number of subjects: 156
Study 17692723 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin gel microspheres 0.1%
Number of subjects: 156
Study 17692723 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as no treatment)
Number of subjects: 156
Study 15498085 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 77
Study 15498085 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 77
Study 15498085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 11697427 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary behavioural treatment
Number of subjects: 27
Study 11697427 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 27
Study 9803573 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help programme for climacteric and menopause, consisting of 10 weekly hour-long sessions including body movement exercises, relaxation, and group discussions.
Number of subjects: 106
Study 9803573 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 106
Study 7634447 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright stress test
Number of subjects: 9
Study 7634447 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine bicycle stress test
Number of subjects: 9
Study 7634447 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal atrial pacing
Number of subjects: 9
Study 2148360 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage phenobarbital and cefotaxime
Number of subjects: 49
Study 2148360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime and phenobarbital combination
Number of subjects: 49
Study 402325 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Carbocain with adrenaline 1:200,000
Number of subjects: 9
Study 402325 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% Citanest with Octapressin 0.03 iu/mul
Number of subjects: 9
Study 402325 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% Carbocain Dental
Number of subjects: 9
Study 402325 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Xylocain with adrenaline 1:80,000
Number of subjects: 9
Study 31352066 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic morcellation
Number of subjects: 86
Study 31352066 — intervention group
Group type: COMPARATOR
Intervention: Loop resection
Number of subjects: 86
Study 30469099 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-oriented alcohol prevention program 'Effekt' (intervention group)
Number of subjects: 985
Study 30469099 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 985
Study 28779928 — intervention group
Group type: EXPERIMENTAL
Intervention: SilAtro‐5‐90 in addition to standard symptomatic treatment
Number of subjects: 256
Study 28779928 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 256
Study 26000670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib
Number of subjects: 90
Study 26000670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 24262397 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free (xylitol) chewing gum
Number of subjects: 30